Our findings that Chk1 activation promotes tau/APP hyperphosphorylation and cognitive dysfunction indicate that pharmacological Chk1 inhibition could reverse AD-like pathological features in DNA-damaged neurons and in the animal model. Here, MAPT is linked to Alzheimer disease.